Royalty Pharma bets an extra half billion on MS candidate
Royalty Pharma has acquired more rights to Biogen’s multiple sclerosis treatment, dimethyl fumarate (Tecfidera).
Royalty announced a payment of 510 million US dollars for the indirect interest in the drug’s sales, paying for the earn-out with cash to former shareholders of Fumapharm AG.
It follows similar payments in May 2012, of 761 million dollars, Royalty said in a statement.
Royalty Pharma acquires additional interest in Tecfidera for $510 million (The Pharma Letter).
Royalty Pharma acquires interest in Biogen drug (The Wall Street Journal).
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.